Catalyst

Slingshot members are tracking this event:

Galmed (GLMD) to Initiate Phase 1/2 Study of Aramchol in Kids with Nonalcoholic Fatty Liver Disease (NAFLD) in H1 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GLMD

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Aramchol, Nonalcoholic Fatty Liver Disease, Nafld, Uc-san Diego School Of Medicine, Artisan